 
        
        
        I-BET151是一种选择性 BET 抑制剂,对 BRD2、BRD3 和 BRD4 的 IC50 分别为 0.5 μM、0.25 μM 和 0.79 μM,在无细胞实验中表现出显著的抑制作用。
 HazMat Fee +
 HazMat Fee + There will be a HazMat fee per item when shipping a dangerous goods. The HazMat fee will be charged to your UPS/DHL/FedEx collect account or added to the invoice unless the package is shipped via Ground service. Ship by air in Excepted Quantity (each bottle), which is up to 1g/1mL for class 6.1 packing group I or II, and up to 25g/25ml for all other HazMat items.
| Type | HazMat fee for 500 gram (Estimated) | 
| Excepted Quantity | USD 0.00 | 
| Limited Quantity | USD 15-60 | 
| Inaccessible (Haz class 6.1), Domestic | USD 80+ | 
| Inaccessible (Haz class 6.1), International | USD 150+ | 
| Accessible (Haz class 3, 4, 5 or 8), Domestic | USD 100+ | 
| Accessible (Haz class 3, 4, 5 or 8), International | USD 200+ | 
 
                                 
                                
                            

| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} | {[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + | 
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解
 
                        
                    
| 产品名称 | BET ↓ ↑ | bromodomain ↓ ↑ | BRPF ↓ ↑ | CBP/beta-catenin ↓ ↑ | p300/CBP ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MS436 | ++ BRD4 (1), Ki: <0.085 μM BRD4 (2), Ki: 0.34 μM | 99%+ | |||||||||||||||||
| CPI-203 | +++ BRD4, IC50: 37 nM | 98+% | |||||||||||||||||
| GSK1324726A | +++ BRD2, IC50: 31 nM BRD4, IC50: 22 nM | 99%+ | |||||||||||||||||
| PFI-1 | ++ BRD2, IC50: 98 nM BRD4, IC50: 0.22 μM | 98% | |||||||||||||||||
| Apabetalone | + BD2, IC50: 0.51 μM | 99% | |||||||||||||||||
| (+)-JQ1 | +++ BRD4 (2), IC50: 33 nM BRD4 (1), IC50: 77 nM | 98% | |||||||||||||||||
| I-BET151 | + BRD4, IC50: 0.5 μM BRD3, IC50: 0.25 μM | 98% | |||||||||||||||||
| Molibresib | +++ BET proteins, IC50: 35 nM | 99%+ | |||||||||||||||||
| I-BRD9 | +++ BRD9, pIC50: 7.3 BRD4, pIC50: 5.3 | 99%+ | |||||||||||||||||
| BI-7273 | ++++ BRD7, IC50: 117 nM BRD9, IC50: 19 nM | 97% | |||||||||||||||||
| Pelabresib | +++ BRD4-BD1, IC50: 39 nM | 98% | |||||||||||||||||
| ARV-825 | +++ BRD4 BD2, Kd: 28 nM BRD4 BD1, Kd: 90 nM | 99%+ | |||||||||||||||||
| Birabresib | 99%+ | ||||||||||||||||||
| BI 2536 | +++ BRD4, Kd: 37 nM | c-Myc | 99%+ | ||||||||||||||||
| Bromosporine | ++ BRD9, IC50: 0.122 μM BRD2, IC50: 0.29 μM | ++++ CECR2, IC50: 17 nM | 99%+ | ||||||||||||||||
| XMD8-92 | ++ BRD4 (1), Kd: 170 nM | 99%+ | |||||||||||||||||
| Mivebresib | ✔ | 99%+ | |||||||||||||||||
| BI-9564 | ++++ BRD7, Kd: 73 nM BRD9, Kd: 5.9 nM | ++ CECR2, Kd: 77 nM | 98% | ||||||||||||||||
| AZD5153 6-Hydroxy-2-naphthoic acid | ++++ FL-BRD4, IC50: 5 nM | 99%+ | |||||||||||||||||
| PLX51107 | ++++ BRD4 BD2, Kd: 1.7 nM BRD3 BD1, Kd: 2.1 nM | 99%+ | |||||||||||||||||
| FL-411 | + BRD4(1), IC50: 0.43 μM | 99%+ | |||||||||||||||||
| ABBV-744 | ✔ | 99%+ | |||||||||||||||||
| dBET6 | ++++ BRD4, IC50: 14 nM | 99%+ | |||||||||||||||||
| dBET1 | ++++ BRD4, IC50: 20 nM | 99%+ | |||||||||||||||||
| MZ1 | ++++ Brd2(BD2), Kd: 62 nM Brd3(BD2), Kd: 13 nM | 99%+ | |||||||||||||||||
| dBET57 | + BRD4BD1, DC50: 500 nM | 99%+ | |||||||||||||||||
| SF2523 | + BRD4, IC50: 241 nM | DNA-PK | 99%+ | ||||||||||||||||
| INCB054329 | ++++ BRD4-BD1, IC50: 119 nM BRD3-BD1, IC50: 9 nM | 99% | |||||||||||||||||
| INCB-057643 | ✔ | 99%+ | |||||||||||||||||
| (E/Z)-ZL0420 | +++ BRD4 BD2, IC50: 32 nM BRD4 BD1, IC50: 27 nM | 99%+ | |||||||||||||||||
| BMS-986158 | ✔ | 99% | |||||||||||||||||
| BRD4 Inhibitor-10 | ++++ BRD4-BD1, IC50: 5 nM BRD4-BD2, IC50: 41 nM | 97% | |||||||||||||||||
| A1874 | ✔ | 99%+ | |||||||||||||||||
| Y06036 | ++ BRD4 (1), Kd: 82 nM | 99%+ | |||||||||||||||||
| Alobresib | ✔ | NF-κB | 95% | ||||||||||||||||
| ODM-207 | ✔ | 98% | |||||||||||||||||
| GSK778 | +++ BRD4-BD1, IC50: 143 nM BRD2-BD1, IC50: 75nM | 97% | |||||||||||||||||
| SRX3207 | + BRD42, IC50: 3070 nM BRD41, IC50: 3070 nM | Syk | 98% | ||||||||||||||||
| GSK046 | +++ BRD3BD2, IC50: 98 nM BRD4BD2, IC50: 214 nM | 98% | |||||||||||||||||
| GSK620 | ✔ | 97% | |||||||||||||||||
| Trotabresib | ✔ | 99% | |||||||||||||||||
| NHWD-870 | ✔ | 98% | |||||||||||||||||
| CFT8634 | ++++ BRD9, DC50: 3 nM | 98% | |||||||||||||||||
| GSK2801 | ++ BAZ2B, Kd: 136 nM BAZ2A, Kd: 257 nM | 99%+ | |||||||||||||||||
| KG-501 | ✔ | 99%+ | |||||||||||||||||
| UNC 669 | + L3MBTL4, IC50: 6 μM L3MBTL3, IC50: 35 μM | 99% | |||||||||||||||||
| PFI-3 | +++ SMARCA4, Kd: 55 nM SMARCA2A, Kd: 72 nM | 99%+ | |||||||||||||||||
| UNC1215 | +++ L3MBTL3, IC50: 120 nM L3MBTL3- D274A, IC50: 3.5 μM | 99%+ | |||||||||||||||||
| EED226 | ++ EED, Kd: 82 nM PRC2, Kd: 114 nM | 99%+ | |||||||||||||||||
| BRD9539 | ✔ | 98% | |||||||||||||||||
| UNC926 | + L3MBTL1, Kd: 3.9 μM | 99% | |||||||||||||||||
| 666-15 | ++ CREB, IC50: 81 nM | 99%+ | |||||||||||||||||
| UNC6852 | + EED, IC50: 247 nM | 98% | |||||||||||||||||
| BAZ1A-IN-1 | + BAZ1A, Kd: 0.52 μM | 99%+ | |||||||||||||||||
| PFI-4 | ++ BRPF1, IC50: 80 nM BRPF2, IC50: 7.9 μM | 99%+ | |||||||||||||||||
| OF-1 | ++ BRPF1B, Kd: 100 nM BRPF2, Kd: 500 nM | 99%+ | |||||||||||||||||
| GSK-5959 | ++ BRPF3, pIC50: 7.1 BRPF2, pIC50: 5.2 | 99% | |||||||||||||||||
| GSK6853 | ++++ BRPF1, pIC50: 8.1 | 99%+ | |||||||||||||||||
| NI-42 | ++++ BRPF1, IC50: 48 nM BRPF3, IC50: 260 nM | 99%+ | |||||||||||||||||
| E-7386 | +++ CBP/beta-catenin, IC50: 0.0484 μM | 99% | |||||||||||||||||
| I-CBP112 | ++ CBP, Kd: 151 nM p300, Kd: 167 nM | 98+% | |||||||||||||||||
| Histone Acetyltransferase Inhibitor II | + p300, IC50: 5 μM | 98% | |||||||||||||||||
| C646 | + p300/CBP, Ki: 400 nM | 99%+ | |||||||||||||||||
| Anacardic Acid | + PCAF, IC50: 5 μM p300/CBP, IC50: 8.5 μM | 99%+ | |||||||||||||||||
| SGC-CBP30 | ++++ EP300, IC50: 38 nM CREBBP, IC50: 21 nM | 99%+ | |||||||||||||||||
| Nordihydroguaiaretic acid | ✔ | HER2,IGF-1R | 99%+ | ||||||||||||||||
| Curcumin | + p300, IC50: ~25 μM | Nrf2,NF-κB,Ferroptosis | 98% | ||||||||||||||||
| CPI-637 | +++ EP300, IC50: 0.051 μM CBP, IC50: 0.03 μM | 99%+ | |||||||||||||||||
| Foscenvivint | ✔ | β-catenin | 99%+ | ||||||||||||||||
| A-485 | ++ p300 HAT, IC50: 0.06 μM | 99%+ | |||||||||||||||||
| GNE-781 | + BRD4(1), IC50: 5100 nM | ++++ CBP, IC50: 0.94 nM | 99% | ||||||||||||||||
| NEO2734 | +++ BET, IC50: <30 nM | +++ p300/CBP, IC50: <30 nM | 99%+ | ||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 靶点 | 
 | 
| 描述 | The Bromodomain and Extra-Terminal Domain BET (Bromodomain and Extra-Terminal Domain) family is characterized by the presence of two tandem bromodomains and an extra-terminal domain. BET proteins can govern the assembly of histone acetylation-dependent chromatin complexes, thus regulating gene expression. I-BET-151 is a potent BET protein inhibitor with IC50 values of 0.5, 0.25 and 0.79 μM for BRD2, BRD3 and BRD4 (measure by FP ligand displacement assay), respectively. I-BET-151 shows more potential and selective effect on growth inhibition of MLL-fusion leukemic cell lines with IC50 values of 15 - 192 nM for MV4-11, RS4-11, MOLM13 and NOMO1 cell lines. Treatment with I-BET-151 for 72h cause a marked induction of apoptosis and a prominent G0/G1 arrest in MOLM13 and MV4-11 cells. This may due to the ability of I-BET-151 to inhibit the transcription of MLL targeted gene such as BCL2, CDK6 or MYC, which regulated by aberrantly co-opted SEC and PAFc in MLL fusions. Treatment with I-BET-151 at dose of 30mg/kg, i.p., daily, for 21 days can provide excellent control of MLL leukemia progression in xenotransplanted model of disseminated human MLL–AF4 leukemia and syngeneic model of murine MLL–AF9 leukemia. Compared with I-BET-762 or JQ1, I-BET-151 showed enhanced in vivo pharmacokinetics and terminal half-life to enable prolonged in vivo studies[1]. I-BET151 has anti-tumor activity in hematological malignancies, including myeloma[2], acute myeloid leukemia[3], lymphoma[4] and myeloproliferative neoplasms[5]. Similar with I-BET-762, I-BET-151 can effectively inhibit IL-6 production in LPS-stimulated PMBCs[6], as well as osteoclast genesis and inflammatory bone resorption[7]. | 
| 作用机制 | I-BET-151 can bind to the acetylated-lysine (AcK) recognition pocket of the BET protein and inhibit the transcription activity of key gene through the displacement of BRD3/4, PAFc and SEC components from chromatin[1]. | 
| 细胞系 | 浓度 | 检测类型 | 检测时间 | 活性说明 | 数据源 | 
| A172 | ~10 μM | Function assay | reduces cellular ATP with IC50 of 1.28 μM | 24496381 | |
| A2 | ~10 μM | Function assay | reactivates latent HIV-1 | 23255218 | |
| A72 | ~10 μM | Function assay | reactivates latent HIV-1 | 23255218 | |
| BC1 | ~1 μM | Growth inhibitory assay | IC50=220 nM | 23792448 | |
| Dose | Rat[8] (p.o.): 2 mg/kg, 10 mg/kg, mice[8] (p.o.): 50 mg/kg | ||||||||||||||||||||||||||||||||||||||||||||||||
| Administration | p.o. | ||||||||||||||||||||||||||||||||||||||||||||||||
| Pharmacokinetics | 
 | 
| 计算器 | ||||
| 存储液制备 |  | 1mg | 5mg | 10mg | 
| 1 mM 5 mM 10 mM | 2.41mL 0.48mL 0.24mL | 12.04mL 2.41mL 1.20mL | 24.07mL 4.81mL 2.41mL | |
| CAS号 | 1300031-49-5 | 
| 分子式 | C23H21N5O3 | 
| 分子量 | 415.44 | 
| SMILES Code | O=C(N1[C@@H](C2=NC=CC=C2)C)NC3=C1C4=CC(OC)=C(C5=C(C)ON=C5C)C=C4N=C3 | 
| MDL No. | MFCD22124472 | 
| 别名 | GSK1210151A | 
| 运输 | 蓝冰 | 
| InChI Key | VUVUVNZRUGEAHB-CYBMUJFWSA-N | 
| Pubchem ID | 52912189 | 
| 存储条件 | In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Sealed in dry, 2-8°C | 
| 溶解方案 | DMSO: 105 mg/mL(252.74 mM),注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶 
 
 
 
 
 
 | 
 沪公网安备 31011702889066号
			
			沪ICP备2024050318号-1
			沪公网安备 31011702889066号
			
			沪ICP备2024050318号-1